Navigation Links
Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
Date:4/14/2008

and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cephalon Quarterly Conference Call Invitation
2. Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
3. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
4. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
5. Cephalon General Counsel John E. Osborn to Resign Position
6. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
7. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
8. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
9. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
10. Cephalon Submits Supplemental New Drug Application for FENTORA
11. Cephalon Announces Strong Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... 2014 The Registration Committee today ... now open for Pittcon 2015, the world’s largest ... event will be held March 8-12, 2015, at ... , The discounted registration fee of $175 ... 2/20/2015). This affordable price includes unlimited week-long access ...
(Date:9/11/2014)... /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") ... it intends to conduct a Private Placement to ... its preclinical development activities and financial commitments to ... The Company is proposing to complete a non-brokered ... at a price of US$0.10 per Share, for ...
(Date:9/11/2014)... Awarded annually by Germany’s Design Zentrum Nordrhein-Westfalen, ... quality label for excellent design. METTLER TOLEDO is ... Red Dot award in recognition of high ... (HPD). , The Quantos Handheld Powder Dispenser ... to applications involving free-flowing powders. Forget the delicacy ...
(Date:9/11/2014)... and LONDON , ... Cancer Research Technology (CRT), the charity,s development and ... (OTCBB: ASTY), a biotechnology company in the emerging ... novel immunotherapy treatment AST-VAC2 into clinical trials in ... AST-VAC2 represents the tenth treatment to enter Cancer ...
Breaking Biology Technology:Conferee Registration Opens for Pittcon 2015; Housing & Travel Open for Reservations 2Portage Announces Proposed Private Placement 2Portage Announces Proposed Private Placement 3Portage Announces Proposed Private Placement 4METTLER TOLEDO Handheld Powder Receives Red Dot Award for Product Design 2Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 2Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 3Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 4Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 5Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 6Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 7Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 8
... Ariz., April 4, 2012  MedPlast, Inc., a technology ... Healthcare and Industrial specialty markets, announces the acquisition ... a world-class, full-service manufacturer of precision plastic products ... Datacenter markets, with operations in the U.S., China, ...
... Lian, assistant professor in the Department of Mechanical, Aerospace, ... a prestigious Faculty Early Career Development Award (CAREER) from ... the five-year, $500,000 award to further his research into ... systems. The CAREER Award is given to faculty members ...
... April 3, 2012  Oxford Finance LLC ("Oxford"), a specialty ... and healthcare services companies, today announced a $15 million ... The financing package, which was awarded to NanoString from ... million senior secured term loan and a $2 million ...
Cached Biology Technology:MedPlast Acquires UPG 2MedPlast Acquires UPG 3Rensselaer professor Jie Lian receives NSF CAREER Award 2Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies 2Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies 3
(Date:9/11/2014)... Northeastern University researchers and their international colleagues have ... role of neutral evolution in the biogeographic distribution ... Thursday in the journal Science . The ... a neutral agent-based model"was co-authored by Ferdi Hellweger, ... of civil and environmental engineering; his doctoral student ...
(Date:9/11/2014)... Sept. 11, 2014 /PRNewswire-iReach/ -- Today at the TEDMED ... patient portal that puts genome sequencing results at the ... and actionable. The $1000 was announced earlier ... to be the tipping point towards widespread adoption of ... billion letters and 4 million variants per human genome, ...
(Date:9/11/2014)... 2014 NXT-ID, Inc. (Nasdaq: NXTD ), ... market, announced today that its shares of common stock and ... Nasdaq Capital Market. The common stock and warrants and will ... today, the Company,s common stock will no longer be quoted ... will now be traded on Nasdaq. About ...
Breaking Biology News(10 mins):Microbes evolve faster than ocean can disperse them 2Tute Genomics Launches MyGene Portal for Genome-guided Medicine 2Tute Genomics Launches MyGene Portal for Genome-guided Medicine 3
... irritants such as air pollution and cigarette smoke cause people ... Journal of Respiratory and Critical Care Medicine . The authors ... of Hull, have identified the reaction inside the lungs that ... irritants in the air. They suggest that their findings may ...
... release is available in German . ... in the atmosphere where it contributes to global warming. The ... as forests, grasslands and peat-lands. Stimulating this "free service" of ... immediately available ways of reducing climate change. However, new greenhouse ...
... A butterfly,s proboscis looks like a straw -- long, slender, ... a paper towel, according to Konstantin Kornev of Clemson University. ... insect anatomy to make small probes that can sample the ... next week at the 62nd Annual Meeting of the American ...
Cached Biology News:Research reveals exactly how coughing is triggered by environmental irritants 2Intensive land management leaves Europe without carbon sinks 2
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Duck polyclonal to Cobra venom - Fab Fragment ( Abpromise for all tested applications). Antigen: Snake Venom of N. naja arta...
LIGHT DIAGNOSTICS Echovirus Blend Reagent, ~50 tests, included in kit #3340 & #3365...
ICAD / DFF45 (NT) Affinity Purified Polyclonal Antibody...
Biology Products: